Hannes Teissl has over 27 years in the biologics and generics industry, in a broad range of international management roles, both operational and strategic. Mr. Teissl joined Polpharma Group in August 2012 as Member (later VP) of the Executive Board, BU Head Biologics and Member of the Supervisory Board of Farmaprojects. He also served as the Group Strategy Officer and became an Advisory Board member for the biosimilars joint venture between the Polpharma and the Strüngmann Group.
.svg)
